NEW Dividend Portfolio Tracker (DRIPTracker) is Now Live!

Track your stocks, dividends, monitor DRIP shares, and project your passive income.

Start Free »

Amgen Inc. AMGN | NASDAQ

$383.43 $0.00 | 0.00%

Next Earnings: Sep 18, 2026

Company Overview:

Market Cap: $0

Trailing PE: 0x

FWD PE *: 16.4x

Payout Ratio (TTM): 60.4%

52-Week Range: $269.77 - $447.03

* Forward PE is based on street estimates.

10 Year AMGN Performance Metrics:

Total Return (with DRIP): 196.6% (11.49% CAGR)

Total Return (no DRIP): 163.2% (10.16% CAGR)

Share Price: 123.7% (8.39% CAGR)

Yield on Cost (with DRIP): 7.80%

Total Invested: $10,000

Total Value (with DRIP): $29,660

Total Return $ (with DRIP): $19,660

Dividend Increase: 119.1% (8.36% CAGR)

Dividend Yield (FWD): 2.63% ($10.08)

AMGN 10-yr Total Return ($10K invested)

1Y 2Y 5Y 10Y All

AMGN Share Price chart

Share Price

AMGN Price CAGR:1Y: 39.01%2Y: 7.32%5Y: 11.81%10Y: 8.39%

AMGN Dividend Charts

AMGN - Dividends

AMGN Dividend CAGR:1Y: 5.88%2Y: 5.83%5Y: 7.44%10Y: 9.68%

AMGN - Dividend Payout Ratio

AMGN - Dividend to Free Cash Flow Ratio

Unlock All Reports & Research Dividend Stocks.

Save 25% with annual plan (3 Months Free)

Pro

$171/yr ($14.25/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Start Free Trial

You save $57/yr (25%)

AMGN Earnings, Revenue, Cash & Debt, Shares Outstanding:

AMGN - Revenue

AMGN Revenue CAGR:1Y: 9.68%2Y: 9.48%5Y: 9.03%10Y: 5.86%

AMGN - Earnings Per Share (EPS)

AMGN EPS CAGR:1Y: 64.91%2Y: 77.95%5Y: 40.09%10Y: 5.87%

AMGN - Net Income

🔒 Unlock

AMGN Net Income CAGR:1Y: 65.85%2Y: 78.43%5Y: 38.62%10Y: 2.42%

AMGN - EBITDA

🔒 Unlock

AMGN EBITDA CAGR:1Y: 25.88%2Y: 23.15%5Y: 14.20%10Y: 6.11%

AMGN - Free Cash Flow

🔒 Unlock

AMGN Free Cash Flow CAGR:1Y: 82.57%2Y: 25.34%5Y: 14.85%10Y: 3.86%

AMGN - Free Cash Flow / Share

🔒 Unlock

AMGN Free Cash Flow / Share CAGR:1Y: 81.90%2Y: 24.99%5Y: 16.22%10Y: 7.34%

AMGN - Operating Income

🔒 Unlock

AMGN Operating Income CAGR:1Y: 32.90%2Y: 35.67%5Y: 33.52%10Y: 3.97%

AMGN - Gross Profit

🔒 Unlock

AMGN Gross Profit CAGR:1Y: 17.66%2Y: 18.57%5Y: 8.18%10Y: 4.56%

AMGN - Shares Outstanding

🔒 Unlock

AMGN Shares Outstanding CAGR:1Y: 0.55%2Y: 0.28%5Y: -1.14%10Y: -3.24%

AMGN - Share Buybacks

🔒 Unlock

AMGN Share Buybacks CAGR:1Y: 0.00%2Y: 0.00%5Y: 0.00%10Y: 0.00%

AMGN - Stock-Based Comp

🔒 Unlock

AMGN Stock-Based Comp CAGR:1Y: 5.10%2Y: 2.52%5Y: 0.00%10Y: 6.61%

AMGN - Expenses

🔒 Unlock

AMGN Expenses CAGR:1Y: 39.02%2Y: 46.81%5Y: 22.63%10Y: 5.98%

AMGN - Revenue vs Net Income

🔒 Unlock

AMGN - EPS vs FCF / Share

🔒 Unlock

AMGN - EPS vs PE Ratio

🔒 Unlock

AMGN - FCF vs FCF / Share

🔒 Unlock

AMGN - FCF vs Stock Based Comp

🔒 Unlock

AMGN - Cash & Debt

🔒 Unlock

AMGN - Revenue by Segment

🔒 Unlock

AMGN Revenue CAGR:1Y: 9.68%2Y: 9.48%5Y: 9.03%10Y: 5.86%

AMGN - Revenue by Region

🔒 Unlock

AMGN Revenue CAGR:1Y: 9.68%2Y: 9.48%5Y: 9.03%10Y: 5.86%

Revenue, EPS, Net Income & Ebitda - Estimates VS Actual:

AMGN - REVENUE: Actual + Estimates

🔒 Unlock

AMGN Actual Revenue CAGR:1Y: 9.68%2Y: 9.48%5Y: 9.03%10Y: 5.86%

AMGN - EPS: Actual + Estimates

🔒 Unlock

AMGN Actual EPS CAGR:1Y: 64.91%2Y: 77.95%5Y: 40.09%10Y: 5.87%

AMGN - NET INCOME: Actual + Estimates

🔒 Unlock

AMGN Actual Net Income CAGR:1Y: 65.85%2Y: 78.43%5Y: 38.62%10Y: 2.42%

AMGN - EBITDA: Actual + Estimates

🔒 Unlock

AMGN Actual EBITDA CAGR:1Y: 25.88%2Y: 23.15%5Y: 14.20%10Y: 6.11%

Ratios, Profit Margins & Return on Capital:

AMGN - Net Profit Margin

🔒 Unlock

AMGN Net Profit Margin CAGR:1Y: 51.22%2Y: 63.00%5Y: 27.14%10Y: -3.25%

AMGN - Gross Profit Margin

🔒 Unlock

AMGN Gross Profit Margin CAGR:1Y: 7.28%2Y: 8.30%5Y: -0.78%10Y: -1.23%

AMGN - Price to Earnings

🔒 Unlock

AMGN - Price To Sales Ratio

🔒 Unlock

AMGN - Return on Capital Employed

🔒 Unlock

AMGN - Return on Invested Capital

🔒 Unlock

AMGN Dividends Info:

Annual Dividend: $10.08

Forward Yield: 2.63%

Ex-Dividend Date: 2026-08-21

Lifetime Dividends / Share: $87.21

AMGN Dividend History: Dates, Payments & Yield list

Below is a schedule of all AMGN dividend payments, ex-dates, share price on the day of the payment as well as the annualized yield & forward yield

Ex-Date	Payment Date	Amount	Yield	Forward Yield	Price on Ex-Date
08/21/2026	08/24/2026	$2.520	2.29%	2.27%	$443.84
05/15/2026	05/18/2026	$2.520	3.09%	3.11%	$324.39
02/13/2026	02/16/2026	$2.520	2.73%	2.73%	$369.53
11/21/2025	11/24/2025	$2.380	2.82%	2.85%	$334.30
08/22/2025	08/25/2025	$2.380	3.24%	3.3%	$288.47
05/16/2025	05/19/2025	$2.380	3.49%	3.45%	$275.85
02/14/2025	02/17/2025	$2.380	3.27%	2.93%	$324.86
11/18/2024	11/20/2024	$2.250	3.23%	3.13%	$287.87
08/16/2024	08/19/2024	$2.250	2.8%	2.74%	$327.97
05/17/2024	06/07/2024	$2.250	0%	2.95%	$305.02
05/16/2024	05/20/2024	$2.250	2.86%	2.86%	$314.54
02/15/2024	02/19/2024	$2.250	3.11%	3.3%	$272.86
11/16/2023	11/20/2023	$2.130	3.17%	3.21%	$265.35
08/17/2023	08/21/2023	$2.130	3.23%	3.27%	$260.70
05/17/2023	05/19/2023	$2.130	3.79%	3.81%	$223.42
02/14/2023	02/16/2023	$2.130	3.53%	3.64%	$234.22
11/16/2022	12/08/2022	$1.940	2.73%	2.72%	$285.57
08/17/2022	09/08/2022	$1.940	3.1%	3.16%	$245.45
05/16/2022	06/08/2022	$1.940	3.18%	3.16%	$245.48
02/14/2022	03/08/2022	$1.940	3.46%	3.36%	$231.10
11/15/2021	12/08/2021	$1.760	3.39%	3.3%	$213.53
08/16/2021	09/08/2021	$1.760	3.05%	3.19%	$220.87
05/14/2021	06/08/2021	$1.760	2.8%	2.97%	$236.82
02/11/2021	03/08/2021	$1.760	3%	3.09%	$227.81
11/13/2020	12/08/2020	$1.600	2.7%	2.8%	$228.94
08/14/2020	09/08/2020	$1.600	2.67%	2.65%	$241.18
05/15/2020	06/08/2020	$1.600	2.66%	2.83%	$225.75
02/13/2020	03/06/2020	$1.600	2.87%	3.04%	$210.65
11/14/2019	12/06/2019	$1.450	2.65%	2.48%	$233.77
08/14/2019	09/06/2019	$1.450	2.92%	2.79%	$207.73
05/16/2019	06/07/2019	$1.450	3.41%	3.3%	$175.51
02/14/2019	03/08/2019	$1.450	3.11%	3.21%	$180.87
11/15/2018	12/07/2018	$1.320	2.74%	2.76%	$191.44
08/16/2018	09/07/2018	$1.320	2.69%	2.69%	$196.30
05/16/2018	06/08/2018	$1.320	3.04%	2.86%	$184.30
02/14/2018	03/08/2018	$1.320	2.94%	2.82%	$187.16
11/16/2017	12/08/2017	$1.150	2.69%	2.62%	$175.41
08/15/2017	09/08/2017	$1.150	2.71%	2.55%	$180.64
05/15/2017	06/08/2017	$1.150	2.88%	2.83%	$162.65
02/13/2017	03/08/2017	$1.150	2.74%	2.59%	$177.78
11/14/2016	12/08/2016	$1.000	2.73%	2.85%	$140.59
08/15/2016	09/08/2016	$1.000	2.29%	2.34%	$170.97
05/13/2016	06/08/2016	$1.000	2.63%	2.53%	$158.00
02/11/2016	03/08/2016	$1.000	2.83%	2.77%	$144.63
11/12/2015	12/07/2015	$0.790	2.09%	2%	$158.30
08/13/2015	09/08/2015	$0.790	1.87%	2.04%	$154.56
05/12/2015	06/05/2015	$0.790	2%	2.01%	$157.25
02/10/2015	03/06/2015	$0.790	2.07%	2.04%	$154.88
11/10/2014	12/05/2014	$0.610	1.5%	1.44%	$169.24
08/12/2014	09/05/2014	$0.610	1.93%	1.77%	$137.88
05/13/2014	06/06/2014	$0.610	2.2%	2.07%	$117.82
02/11/2014	03/07/2014	$0.610	2.01%	2%	$122.26
11/12/2013	12/06/2013	$0.470	1.67%	1.65%	$114.12
08/14/2013	09/06/2013	$0.470	1.76%	1.69%	$111.01
05/14/2013	06/07/2013	$0.470	1.74%	1.9%	$98.81
02/11/2013	03/07/2013	$0.470	2.21%	2.02%	$92.95
11/13/2012	12/07/2012	$0.360	1.68%	1.63%	$88.32
08/14/2012	09/07/2012	$0.360	1.72%	1.72%	$83.96
05/14/2012	06/07/2012	$0.360	2.05%	2.08%	$69.10
02/13/2012	03/07/2012	$0.360	2.11%	2.15%	$66.95
11/15/2011	12/08/2011	$0.280	1.98%	1.92%	$58.40
08/16/2011	09/08/2011	$0.280	2.18%	2.02%	$55.31

Projected Future Returns & Dividends for AMGN

Based on past 10-year performance, here are AMGN growth metrics:

Share price CAGR of +8.39%
Dividend CAGR of +9.73%

Using AMGN CAGR metrics, we can estimate that your initial $10000 investment, over the next 10 years, is modelled to grow as follows:

	AMGN (DRIP)	AMGN - No DRIP
Current Price	$383.43	$383.43
Start Shares	26.08	26.08
Start Value	$10,000	$10,000

After 10 years:
Final Share Count	33.89	26.08
Dividends Payment	$5.64	$5.64
Annual Dividends	$764	$588
Yield on cost	7.64%	5.88%
Share Price	$857.85	$857.85
Total Dividends	$4,496	$3,879
Final Value	$29,075	$26,252

Estimated Future Value + Dividends - AMGN

NOTE: Above numbers are our estimate based on AMGN's Dividend and Price CAGR over past 10 years. These numbers should only be considered as "potential future returns"! DRIP assumes reinvesting dividends; No-DRIP assumes collecting dividends as cash.

We cannot guarantee that your actual returns will meet these estimates.

Get the best Dividend Stock Research Tools:

Save 25% with annual plan (3 Months Free)

Pro

$171/yr ($14.25/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Start Free Trial

You save $57/yr (25%)

Company Info

Amgen Inc. (AMGN) had its IPO on 1983-06-17, and is trader on NASDAQ stock exchange.

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

AMGN website: https://www.amgen.com

Get Full Access to All Reports with DRIPCalc PRO

Save 25% with annual plan (3 Months Free)

Pro

$171/yr ($14.25/mo)

7-day free trial

Unlimited Portfolio Tracker
Portfolio - Lots/Sales/Dividends
Portfolio Auto-DRIP
Stock Fundamentals
DCF valuation modeling
Compare Stocks Side-by-Side
Revenue & EPS Estimates

Start Free Trial

You save $57/yr (25%)